Lifeward Appoints Bob Marshall as Chairman of the Board
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
Lifeward (NASDAQ:LFWD) had its price target lowered by analysts at HC Wainwright from $13.00 to $4.50. They now have a "buy" rating on the stock.
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton